Market Cap 6.12B
Revenue (ttm) 0.00
Net Income (ttm) -96.21M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 6,347,000
Avg Vol 6,722,514
Day's Range N/A - N/A
Shares Out 115.52M
Stochastic %K 85%
Beta -0.37
Analysts Hold
Price Target $53.00

Company Profile

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phas...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 525 5535
Fax: 650 275 4254
Address:
1065 East Hillsdale Boulevard, Suite 100, Foster City, United States
amessagefromtheodd
amessagefromtheodd May. 30 at 11:02 AM
$ALMS $CAPR $SLS $TERN There is more to see 💎 🙌🏿
1 · Reply
Sihtegroftnod
Sihtegroftnod May. 30 at 12:58 AM
$ALMS $CAPR $SLS $TERN This! Right here!!
0 · Reply
BIOTECH_GURU
BIOTECH_GURU May. 30 at 12:48 AM
$SLS they want the retail to sell. They dropped prices for multiple recent biotechs right before the rip. $TERN $CAPR $ALMS Hold the line or regret being Mcpaperhands.
0 · Reply
YouVSYou
YouVSYou May. 26 at 1:46 AM
Eli Lilly’s one-time gene editing therapy cut LDL cholesterol by 62% in Phase 1 trial participants, with effects lasting up to 18 months. No serious adverse events reported. $LLY $NVO $HIMS $TERN
0 · Reply
jcooptechit
jcooptechit May. 22 at 4:56 PM
$CUE | CATALYST TIMELINE IS STACKING 🔥 Cue Biopharma is entering a major value-driving window with multiple 2H 2026 milestones ahead. ▫️ CUE-221 Phase 2 China data expected 2H 2026 ▫️ Food allergy IND amendment planned ▫️ CUE-401 IND filing expected 2H 2026 ▫️ Phase 1 first-in-human targeted by year-end ▫️ $7.5M Boehringer milestone validates the platform ▫️ $30M financing strengthens execution This is now a clinical-stage immunology/allergy story with big catalysts lining up. Keep CUE on close watch going into data. 🧐 Communicated - Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $IMVT $KYTX $CABA $TERN
1 · Reply
MilsLearning
MilsLearning May. 22 at 9:37 AM
0 · Reply
BIOTECH_GURU
BIOTECH_GURU May. 20 at 1:49 PM
$SLS $CAPR $TERN $ALMS $SLS paperhands should be ashamed of selling this anywhere less than $20
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 18 at 4:08 PM
$TERN RSI: 85.71, MACD: 0.7869 Vol: 0.13, MA20: 52.83, MA50: 49.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 5:29 PM
$SLS - pardon me @Maxamillion5000, i know some are just getting to know... and for anyone interested in MONEY. https://www.reddit.com/r/sellasLifescience/search/?q=aml-mr&cId=057d1aab-2b7d-4bf0-a2d4-c3227af101f8&iId=8d5110f2-0189-40ea-bc04-b363b5cad724 - link for 009 DD. SLS009 is the only Effective Agent for the Most Dire AML Prognosis, AML-MR - Mutations TP53 Asxl1 Runx Ezh2 -- AML that is mutated, often after Chemo from other cancers. SLS009 has direct market Comps $TERN $FTSV both bought for $5B+ based on Lesser PH2B DATA SLS009 Published at ASH.
0 · Reply
judgeyoung2
judgeyoung2 May. 5 at 5:10 PM
$GEV sold this right after the spin off. sold $TERN at $7 lmao. i just need to not touch things.
1 · Reply
Latest News on TERN
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

May 5, 2026, 8:45 AM EDT - 27 days ago

Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

MRK


Terns Pharmaceuticals Annual report: Q4 2025

Mar 30, 2026, 7:00 AM EDT - 2 months ago

Terns Pharmaceuticals Annual report: Q4 2025


Terns Pharmaceuticals Transcript: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Terns Pharmaceuticals Transcript: M&A announcement


Terns Pharmaceuticals Slides: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Terns Pharmaceuticals Slides: M&A announcement


Terns Pharmaceuticals Press release: M&A announcement

Mar 25, 2026, 8:00 AM EDT - 2 months ago

Terns Pharmaceuticals Press release: M&A announcement


Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

Mar 25, 2026, 6:49 AM EDT - 2 months ago

Merck Reaches Nearly $6 Billion Deal for Cancer Biotech Terns

MRK


Terns Pharmaceuticals Slides: Corporate presentation

Jan 12, 2026, 7:00 AM EST - 5 months ago

Terns Pharmaceuticals Slides: Corporate presentation


Terns CEO Amy Burroughs talks cancer drug trial win

Dec 15, 2025, 6:31 PM EST - 5 months ago

Terns CEO Amy Burroughs talks cancer drug trial win


Terns Announces Pricing of Upsized $650 Million Public Offering

Dec 9, 2025, 11:30 PM EST - 6 months ago

Terns Announces Pricing of Upsized $650 Million Public Offering


Cancer Study Buoys These Small Biotechs

Dec 9, 2025, 3:31 PM EST - 6 months ago

Cancer Study Buoys These Small Biotechs

ACLX LEGN


Terns Announces Proposed Public Offering

Dec 9, 2025, 6:12 AM EST - 6 months ago

Terns Announces Proposed Public Offering


Terns Pharmaceuticals Transcript: Study Update

Dec 8, 2025, 4:30 PM EST - 6 months ago

Terns Pharmaceuticals Transcript: Study Update


Terns Pharmaceuticals Press release: Study Update

Dec 8, 2025, 4:30 PM EST - 6 months ago

Terns Pharmaceuticals Press release: Study Update


Terns Pharmaceuticals Slides: Study Update

Dec 8, 2025, 4:30 PM EST - 6 months ago

Terns Pharmaceuticals Slides: Study Update


Terns Pharmaceuticals Quarterly report: Q3 2025

Nov 10, 2025, 4:00 PM EST - 7 months ago

Terns Pharmaceuticals Quarterly report: Q3 2025


Terns Pharmaceuticals Earnings release: Q3 2025

Nov 10, 2025, 4:00 PM EST - 7 months ago

Terns Pharmaceuticals Earnings release: Q3 2025


Terns Pharmaceuticals Transcript: Study Update

Sep 3, 2025, 4:30 PM EDT - 9 months ago

Terns Pharmaceuticals Transcript: Study Update


Terns Pharmaceuticals Slides: Study Update

Sep 3, 2025, 4:30 PM EDT - 9 months ago

Terns Pharmaceuticals Slides: Study Update


Terns Pharmaceuticals Quarterly report: Q2 2025

Aug 5, 2025, 4:00 PM EDT - 10 months ago

Terns Pharmaceuticals Quarterly report: Q2 2025


Terns Pharmaceuticals Earnings release: Q2 2025

Aug 5, 2025, 4:00 PM EDT - 10 months ago

Terns Pharmaceuticals Earnings release: Q2 2025


Terns Pharmaceuticals Slides: Corporate Presentation

Jun 6, 2025, 7:00 AM EDT - 1 year ago

Terns Pharmaceuticals Slides: Corporate Presentation


Terns Pharmaceuticals Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q1 2025


Terns Pharmaceuticals Quarterly report: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Quarterly report: Q1 2025


Terns Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Proxy statement: Proxy Filing


Terns Pharmaceuticals Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

Terns Pharmaceuticals Proxy statement: Proxy Filing


Terns Pharmaceuticals Earnings release: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Earnings release: Q4 2024


Terns Pharmaceuticals Annual report: Q4 2024

Mar 20, 2025, 4:00 PM EDT - 1 year ago

Terns Pharmaceuticals Annual report: Q4 2024


Terns Pharmaceuticals Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

Terns Pharmaceuticals Slides: FY 2025


Terns Pharmaceuticals Transcript: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Transcript: Study Result


Terns Pharmaceuticals Press release: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Press release: Study Result


Terns Pharmaceuticals Slides: Study Result

Dec 3, 2024, 8:00 AM EST - 1 year ago

Terns Pharmaceuticals Slides: Study Result


Terns Pharmaceuticals Quarterly report: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Terns Pharmaceuticals Quarterly report: Q3 2024


Terns Pharmaceuticals Earnings release: Q3 2024

Nov 12, 2024, 9:30 AM EST - 1 year ago

Terns Pharmaceuticals Earnings release: Q3 2024


amessagefromtheodd
amessagefromtheodd May. 30 at 11:02 AM
$ALMS $CAPR $SLS $TERN There is more to see 💎 🙌🏿
1 · Reply
Sihtegroftnod
Sihtegroftnod May. 30 at 12:58 AM
$ALMS $CAPR $SLS $TERN This! Right here!!
0 · Reply
BIOTECH_GURU
BIOTECH_GURU May. 30 at 12:48 AM
$SLS they want the retail to sell. They dropped prices for multiple recent biotechs right before the rip. $TERN $CAPR $ALMS Hold the line or regret being Mcpaperhands.
0 · Reply
YouVSYou
YouVSYou May. 26 at 1:46 AM
Eli Lilly’s one-time gene editing therapy cut LDL cholesterol by 62% in Phase 1 trial participants, with effects lasting up to 18 months. No serious adverse events reported. $LLY $NVO $HIMS $TERN
0 · Reply
jcooptechit
jcooptechit May. 22 at 4:56 PM
$CUE | CATALYST TIMELINE IS STACKING 🔥 Cue Biopharma is entering a major value-driving window with multiple 2H 2026 milestones ahead. ▫️ CUE-221 Phase 2 China data expected 2H 2026 ▫️ Food allergy IND amendment planned ▫️ CUE-401 IND filing expected 2H 2026 ▫️ Phase 1 first-in-human targeted by year-end ▫️ $7.5M Boehringer milestone validates the platform ▫️ $30M financing strengthens execution This is now a clinical-stage immunology/allergy story with big catalysts lining up. Keep CUE on close watch going into data. 🧐 Communicated - Disclaimer: https://stockresearchtoday.com/cue/ Sector Peers: $IMVT $KYTX $CABA $TERN
1 · Reply
MilsLearning
MilsLearning May. 22 at 9:37 AM
0 · Reply
BIOTECH_GURU
BIOTECH_GURU May. 20 at 1:49 PM
$SLS $CAPR $TERN $ALMS $SLS paperhands should be ashamed of selling this anywhere less than $20
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 18 at 4:08 PM
$TERN RSI: 85.71, MACD: 0.7869 Vol: 0.13, MA20: 52.83, MA50: 49.92 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 May. 15 at 5:29 PM
$SLS - pardon me @Maxamillion5000, i know some are just getting to know... and for anyone interested in MONEY. https://www.reddit.com/r/sellasLifescience/search/?q=aml-mr&cId=057d1aab-2b7d-4bf0-a2d4-c3227af101f8&iId=8d5110f2-0189-40ea-bc04-b363b5cad724 - link for 009 DD. SLS009 is the only Effective Agent for the Most Dire AML Prognosis, AML-MR - Mutations TP53 Asxl1 Runx Ezh2 -- AML that is mutated, often after Chemo from other cancers. SLS009 has direct market Comps $TERN $FTSV both bought for $5B+ based on Lesser PH2B DATA SLS009 Published at ASH.
0 · Reply
judgeyoung2
judgeyoung2 May. 5 at 5:10 PM
$GEV sold this right after the spin off. sold $TERN at $7 lmao. i just need to not touch things.
1 · Reply
Floridaorange
Floridaorange May. 4 at 3:45 PM
$RXRX notice the yearly chart looks like every beatdown SaaS stock? That’s because the market is not accurately valuing or categorizing $RXRX. Miscategorized = mispriced. Earnings this Wed could be the shift. $SMMT $TERN $VKTX
1 · Reply
kubota2323
kubota2323 May. 2 at 2:45 AM
$TERN welp
0 · Reply
kingofking719
kingofking719 Apr. 30 at 6:07 PM
$UAMY $BULL $SOUN $TERN @JarvisProtocols we don't care
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 4:10 PM
$SLS SLS009 Pristine Safety Profile Durable Efficacy, for the most Dire of AML Mutations, worth more than $TERN and $FTSV You will wish you bought more. We All Will.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 3:38 PM
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 30 at 1:46 AM
$SLS $MRK $TERN Dr. Khan one of the Phase 2 clinicians, explains the ongoing pivotal randomized SLS PH2B AML-MR Expansion, Front line results, will be even better than the Prior P2B results in end stage setting. - this was before Harvard Prof, Dr. Amrein discovered a 3 fold More Potent dosing regime. - direct link below - worth a listen for those buying in now on the market tankage. . . . - BUY AND HOLD ALL THAT YOU CAN - your future you will thank you. Joshua F. Zeidner, MD — University of North Carolina, Lineberger Comprehensive Cancer Center (lead author) Omer Jamy — O'Neal Comprehensive Cancer Center, University of Alabama-Birmingham Bradley Christensen — Baylor Scott & White Research Institute Sharif Khan — Bon Secours Hematology & Oncology Dragan Cicic — SELLAS Life Sciences Group Tapan Kadia, MD — MD Anderson Cancer Center
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 29 at 10:56 PM
$SLS $MRK $TERN Just the Secondary Asset, SLS009 is worth at Least what GILD Paid for FTSV / $4.9B / $27 Per SLS Share - A Guaranteed 600% ROI - Should See 6 or 7 PR's in the Next 6 to7 months, including Final Randomized Pivotal Results and the AML-IMPACT EU PR in Q2.
0 · Reply
romanaround
romanaround Apr. 29 at 10:12 PM
$ALT $BIOA $TERN $VKTX gosh dang my apologies to tern and bioa they are on top kings
0 · Reply
DonCorleone77
DonCorleone77 Apr. 29 at 7:54 PM
$TERN Attached is a Mizuho analyst note regarding TERN issued today.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Apr. 29 at 7:21 PM
$SLS $GILD 20% of all AML Patients are AML-MR SLS009 Phase 2B Results in End Stage AML-MR Confirm SLS009 is RIGHT NOW worth More Than the $4.9B GILD Paid for FTSV - and the $7B $MRK paid for $TERN Just the Secondary Asset Guarantees SLS Investors at LEAST a 600% ROI - and a 5,000% + FREE ROLL when GPs Phase 3 Results are Announced. Could be any day.
0 · Reply
TwongStocks
TwongStocks Apr. 28 at 6:15 PM
$TERN Equity Corporate Actions Alert #2026 - 286 Information Regarding the Tender Offer of Terns Pharmaceuticals, Inc. (TERN) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-286 The tender offer by $MRK to acquire all of the outstanding common stock of $TERN is scheduled to expire one minute after 11:59 p.m. ET, on May 4, 2026, unless extended or terminated. If successful, the subsequent merger is tentatively scheduled to close prior to the market open on May 5, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 4, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 5th) and will be suspended effective May 6, 2026. TERN shareholders will receive $53 for each share held.
0 · Reply
DonCorleone77
DonCorleone77 Apr. 27 at 9:25 PM
$TERN Attached is page 1 of a Oppenheimer analyst report regarding TERN issued yesterday.
0 · Reply